Hepatitis Still a Frustrating (Hepatitis C Treatment Options) Foe

Hepatitis Still a Frustrating Foe
TheStreet.com - Apr 05 9:44 AM
Despite the efforts of a slew of companies, the virus refuses to give up the fight.Save to My Web

Chinese Patients With Chronic Hepatitis B Respond Better To Telbivudine Than Lamivudine
Medical News Today - Mar 27 4:05 PM
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and Novartis (NYSE: NVS) todayannounced new data that demonstrate telbivudine, an investigational oral,once-daily nucleoside analogue, provided significantly greater antiviral andclinical efficacy in Chinese patients with chronic hepatitis B (CHB) afterone-year of treatment when compared with a current standard of care,lamivudine... click link for more Save to My Web

Hepatitis C Market: Plenty Of Potential,But Little Progress
Investor's Business Daily via Yahoo! News - Mar 31 4:00 PM
The month of March was not kind to a pair of companies racing to find a cure or vaccine for hepatitis C, the often fatal liver disease that's been called a global epidemic by the World Health Organization.Save to My Web